NCT00547261
Terminated
Phase 1
Phase I Dose Escalation and Pharmacokinetic Study of SSR97225 Administered as a 1 Hour IV Infusion D1 Every 3 Weeks (Arm A) or Administered as a 1hour IV Infusion D1, D8, D15 Every 3 Weeks (Arm B) in Patients With Refractory Solid Tumors
Overview
- Phase
- Phase 1
- Intervention
- SSR97225
- Conditions
- Neoplasms
- Sponsor
- Sanofi
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- Maximal tolerated dose (MTD) and dose limiting toxicity (DLT)
- Status
- Terminated
- Last Updated
- 17 years ago
Overview
Brief Summary
The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of metastatic or locally advanced non-hematological cancer
- •Patients with solid tumors refractory to therapy or for whom no therapy exists
Exclusion Criteria
- •Five or more prior chemotherapy lines for metastatic disease
- •Eastern Cooperative Oncology Group (ECOG) performance status \>2
- •Patients having discontinued previous specific anti-cancer treatment
- •Patients who have not recovered from all toxic effects from previous specific anti-cancer treatment (excluding alopecia)
- •Patients with abnormal biological/hematological parameters, cardiac abnormalities or serious infection/intercurrent illness likely to jeopardize the patient's safety or the course of the protocol treatment
- •No adequate birth control methods
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Arms & Interventions
Arm A
1 hour IV infusion D1
Intervention: SSR97225
Arm B
1 hour IV infusion D1, D8, D15
Intervention: SSR97225
Outcomes
Primary Outcomes
Maximal tolerated dose (MTD) and dose limiting toxicity (DLT)
Time Frame: Study period
Secondary Outcomes
- Pharmacokinetic profile, antitumor activity in patients with measurable disease, effect of drug on CYP3A4 activity(Study period)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian CancerEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerNCT02480374Imunon18
Completed
Phase 1
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36
Completed
Phase 1
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)Solid TumorsLymphoma, Non-HodgkinMultiple MyelomaLeukemia, Lymphocytic, Chronic. B-CellNCT00871663Merck Sharp & Dohme LLC123
Terminated
Phase 1
Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual DiseaseLeukemia, MyeloidMyelodysplastic SyndromesNCT02370888University of Florida11
Terminated
Phase 1
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological MalignanciesLymphoid Hematological MalignanciesRelapsed and Refractory Multiple MyelomaNCT02223598Cleave Biosciences, Inc.120